Literature DB >> 3689694

Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years.

Y Najean1, P Mugnier, C Dresch, J D Rain.   

Abstract

Over 20 years, 58 cases of PV in young people (46 meeting the full PVSG criteria, 12 with elevated red cell volume and leucocytosis or thrombocytosis, without splenomegaly) were studied and have been followed for periods of 3-24 years. These cases represent approximately 5% of the cases of PV referred to the Department of Nuclear Medicine of St Louis Hospital during this period. They differ from older patients in the initial clinical severity, the short interval between the first symptoms and the diagnosis, frequent presentation with a life-threatening complication (two cases of hepatic vein thrombosis, six thrombotic or haemorrhagic events, six splenectomies, two abortions) and a very enlarged spleen in half the cases. However, after the initial complications, the overall survival is very long (exceeding 70%, even when including the initial complications, at 15 years). The vascular accidents occur exclusively in the phlebotomized patients, the main risk factor being the poor stability of the haematocrit. Only one acute leukaemia was observed among the 14 cases treated by radioactive phosphorus and/or alkylating chemotherapy. The most frequent late complication was evolution towards myelofibrosis. This spent phase seemed to occur earlier in patients treated by phlebotomy. On the basis of this data, we would advise the following therapeutic strategy: phlebotomies, as soon as the diagnosis is established, and a systematic long-term treatment by hydroxyurea with the hope of reducing the number of vascular complications and of delaying the evolution towards the spent phase and the myelofibrosis.

Entities:  

Mesh:

Year:  1987        PMID: 3689694     DOI: 10.1111/j.1365-2141.1987.tb02349.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Treatment of polycythemia vera with recombinant interferon.

Authors:  Richard T Silver
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Treatment outcome in a cohort of young patients with polycythemia vera.

Authors:  Marco Ruggeri; Silvia Finotto; Stefania Fortuna; Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

Review 3.  Coagulation abnormalities and cerebral infarction.

Authors:  M Greaves
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

4.  New and old prognostic factors in polycythemia vera.

Authors:  Francesco Passamonti
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

5.  A case of polycythaemia vera presenting with intramuscular chest wall haematoma.

Authors:  S Kheterpal; F Sayegh; A Cader
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

6.  Thrombocytosis in young people: evaluation of 57 cases diagnosed before the age of 40.

Authors:  M L Randi; F Fabris; A Girolami
Journal:  Blut       Date:  1990-04

7.  Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.

Authors:  A Wehmeier; I Daum; H Jamin; W Schneider
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

Review 8.  Clinical and hematological presentation of children and adolescents with polycythemia vera.

Authors:  Holger Cario; Mary Frances McMullin; Heike L Pahl
Journal:  Ann Hematol       Date:  2009-05-26       Impact factor: 3.673

9.  Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China.

Authors:  Jie Bai; Yangping Xue; Lei Ye; Jianfeng Yao; Chunlin Zhou; Zonghong Shao; Linsheng Qian; Renchi Yang; Haiyan Li; Hongyun Zhang; Yizhou Zheng
Journal:  Int J Hematol       Date:  2008-11-11       Impact factor: 2.490

Review 10.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.